- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about SNY
Recent news which mentions SNY
Earnings Scheduled For October 28, 2022
October 28, 2022
From Benzinga
Tickers
SNY
From MarketWatch
From Motley Fool
US Stock Futures Lower Following Friday's Rally; Tesla In Focus
October 24, 2022
From Benzinga
New Drugs Approvals Bring No Relief for Ailing Innovent Bio
October 18, 2022
From Benzinga
From Motley Fool
3 Red-Hot Stocks That Could Continue to Beat the Market
October 13, 2022
From Motley Fool
From Benzinga
2 Top Healthcare Stocks to Buy Right Now
October 08, 2022
From Motley Fool
7 Under-$50 Stocks to Buy to Tap Into a Hidden Bull Market
October 07, 2022
From InvestorPlace
Sanofi, Provention Bio Ink Co-Promotion Pact For Type 1 Diabetes Treatment Candidate
October 06, 2022
From Benzinga
From Motley Fool
Regeneron-Sanofi's Flagship Dupixent Becomes First FDA-Approved Treatment For Prurigo Nodularis
September 29, 2022
From Benzinga
Haleon Shares Pop After Rejecting Zantac Indemnification Requests From GSK, Pfizer
September 20, 2022
From Benzinga
Multiple Sclerosis Is A Crowded Space, But This Stock Is A Potential 6X Multi-bagger
September 19, 2022
From Benzinga
2 Biotech Stocks You Can Buy and Hold for the Next Decade
September 19, 2022
From Motley Fool
AstraZeneca's COVID-19 Antibody Cocktail, RSV Treatment For Infants Gets European Authority Backing
September 16, 2022
From Benzinga
From Benzinga
What's Moderna's Next Billion-Dollar Market? The Answer May Surprise You.
September 14, 2022
From Motley Fool
Regeneron-Sanofi Eczema Drug Shows Improvements In Itchy Inflammatory Skin Disease
September 08, 2022
From Benzinga
Sanofi-GSK COVID-19 Vaccine May See European Approval Soon: Report
September 06, 2022
From Benzinga
Sanofi-Regeneron's Flagship Drug Shows Consistent Efficacy, Safety Profile At Two Years For Asthma In Kids
September 06, 2022
From Benzinga
From Benzinga
Sanofi's Rare Disease Drug Xenpozyme Scores FDA Approval
September 01, 2022
Tickers
SNY
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.